Philip Morris International Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Philip Morris International Inc. trades at $195 (market cap $293.07B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Philip Morris International Inc. is far larger — about 17× Zimmer Biomet Holdings Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.13%). Which is the better fit depends on your goals.
| PM | ZBH | |
|---|---|---|
Market Cap | $293.07B | $17.20B |
Sector | Consumer Staples | Health |
52-Week High | $192.98 | $107.71 |
52-Week Low | $144.33 | $79.58 |
Enterprise Value | $339.57B | $24.25B |
Dividend Yield | 3.13% | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $192.72, down 0.13% on the day, with strong analyst support (17 buy ratings) and a $194 consensus price target. The stock shows bullish technical momentum above key support levels, while fundamentals reveal robust profitability with 26.74% net margins and consistent revenue growth to $40.65B in 2025. Recent news includes a profit forecast revision due to a $500M impairment charge and CFO succession planning.
PM offers stable dividend income and brand strength but faces headwinds from cost pressures and illicit market growth. The stock trades at a premium valuation (P/E 27.13) with elevated debt levels, requiring monitoring of pricing power and regulatory developments. Near-term catalysts include Q2 earnings and execution of the smoke-free transition strategy.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →